Lineage Cell Therapeutics reported that the company's proprietary AlloSCOPE platform ? Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering ? enables the manufacture of millions of doses of cell-based products derived from a single initial cell line.
In its January 2026 shareholder letter, Lineage disclosed it is now evaluating AlloSCOPE as a solution to the massive production scale required for commercially-viable islet cell therapy in Type 1 Diabetes ? a program that runs thematically parallel to Avaí Bio's own diabetes and anti-aging efforts through encapsulated cells. Lineage also achieved a first milestone under its worldwide collaboration with Roche's Genentech for OpRegen, an allogeneic retinal pigment epithelium cell therapy being developed for geographic atrophy secondary to age-related macular degeneration.
Together with new corneal endothelial (COR1) and additional undisclosed cell programs, Lineage's expanding pipeline illustrates how cell-based regenerative platforms are being repositioned from niche indications toward broader applications in age-related disease.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The Company programs are based on a cell-based technology platform, AlloSCOPE, which develops formulation, manufacturing, and delivery capabilities, and serves as the source of its pluripotent cell-based product candidates. Its pipeline includes OpRegen, an allogeneic retinal pigment epithelial (RPE) cell replacement therapy for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (dry-AMD); OPC1, an allogeneic oligodendrocyte progenitor cell therapy for the treatment of spinal cord injuries (SCI); ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant therapy for the treatment of auditory neuropathy; ILT1, an allogeneic cell transplant research initiative for the treatment of Type 1 Diabetes (T1D).
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
-
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
-
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
-
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
